Smartphone memory tests detect Alzheimer’s decline months earlier

A quiet shift in memory can begin long before a diagnosis of dementia. These early changes often pass unnoticed, even as the brain slowly alters. New research suggests that simple digital tools, used regularly at home, may detect these changes far sooner than traditional methods.

A study led by the German Center for Neurodegenerative Diseases, in collaboration with international partners including the University of Wisconsin–Madison, shows that smartphone-based memory tests can track subtle cognitive decline within months.

Researchers say this approach could reshape how conditions like Alzheimer’s disease are studied and monitored, especially in their earliest stages.

Cognitive decline often unfolds slowly. People with mild cognitive impairment, or MCI, may still manage daily life with little difficulty. Yet their memory and thinking abilities show measurable changes.

Doctors have long relied on in-person assessments to track these changes. These tests require scheduled visits, supervision, and standardized tasks. Because they take time and resources, they are usually done once or twice a year.

That gap creates a problem. Subtle changes that happen between visits may go unnoticed.

Dr. David Berron, a researcher involved in the study, explains the limitation clearly. “Conventional methods for assessing cognitive performance are based on standardized tasks that must be completed orally or in writing, and importantly, under supervision,” he said.

The study tested a different approach. Participants used a mobile app to complete memory exercises on their own devices. These tests were short, simple, and repeated regularly over several months.

The app, developed by the German start-up neotiv, measures different types of memory. Tasks include remembering objects, recalling locations, and spotting differences between images. Each task targets specific brain regions affected during disease progression.

Dr. Sarah Polk, first author of the study, highlighted the convenience. “Testing can be done at home, at your own pace,” she said. “All you need is a smartphone or tablet, there’s no need to visit a study center or make an appointment.”

This flexibility allowed participants to test themselves every two weeks over a period of seven to twelve months.

Frequent testing proved to be the key advantage. By collecting more data points, researchers could detect patterns that would otherwise remain hidden.

In participants with mild cognitive impairment, the app revealed a steady decline in memory performance within months. Traditional methods would likely require years to capture the same trend.

Polk emphasized the importance of this frequency. “With the conventional approach, testing is realistically possible only once or twice a year,” she said. “In contrast, our participants tested themselves about every two weeks.”

This high-frequency monitoring allowed researchers to observe changes in real time, rather than waiting for large shifts to appear.

To confirm that the digital tests were reliable, researchers compared the app results with long-term clinical records. Each participant had data collected over an average of eight years using established methods.

The comparison showed strong agreement. Short-term changes measured through the app aligned closely with long-term trends observed in clinical assessments.

Polk noted the significance of this finding. “With just a few months of app use, we were able to capture a signal that aligns with years of clinical observations,” she said. “That gives us confidence that this method really measures what it is supposed to measure.”

The study also revealed that not all types of memory decline at the same pace.

Some tasks showed strong impairment at the beginning of the study. These included memory functions linked to brain regions already affected by disease. Because these areas had already reached a low level of function, no further decline could be measured.

Other tasks, however, showed gradual worsening over time. These functions appear to decline later in the disease process, making them easier to track in ongoing monitoring.

Berron explained the pattern. “This suggests that the associated brain regions had already been damaged to such an extent that they had reached the lower limit of their functional capacity,” he said.

This layered view of memory decline offers a clearer picture of how diseases like Alzheimer’s progress through the brain.

The findings suggest that digital tools may detect cognitive changes even before mild cognitive impairment becomes obvious.

Berron believes this is a key next step. “In the earliest disease stage, subtle cognitive impairment may already be present that we simply cannot measure using conventional tests,” he said.

By capturing these early signals, researchers may be able to identify risk sooner and begin intervention earlier.

One of the most immediate uses of this technology lies in clinical trials.

Developing treatments for dementia requires measuring whether a drug slows cognitive decline. Traditional testing methods make this process slow and expensive, often requiring years to see results.

Digital testing could speed this up.

“A digital approach could help speed up clinical trials,” Berron said. “It could make it possible to determine whether the drug being tested has the desired effect more quickly than with conventional methods.”

Faster trials could accelerate the development of new therapies, particularly for Alzheimer’s disease.

Beyond research, the study points to future use in everyday healthcare.

Doctors could use digital tools to monitor patients over time, tracking whether cognitive abilities remain stable or worsen. This could help guide treatment decisions and provide earlier warnings of decline.

Berron outlined two key applications. First, assessing whether cognitive abilities are developing as expected with age. Second, monitoring ongoing treatments to evaluate their effectiveness.

This shift would move care from occasional checkups to continuous observation.

Digital testing also offers broader accessibility. Because the tests can be done at home, they remove the need for travel and scheduling. This could make cognitive monitoring more available to people in remote or underserved areas.

The tasks are also non-verbal, which allows them to be used across different languages and cultures.

Researchers believe this scalability could support large-scale studies and improve global understanding of cognitive health.

Despite the promise, the approach still faces challenges.

The study involved a relatively small group of participants. Larger studies will be needed to confirm the findings and refine the methods.

There are also questions about long-term engagement. While participants showed strong adherence during the study, maintaining regular testing over years may be more difficult.

Researchers also note that the app does not provide direct feedback to users. Results are interpreted by medical professionals, ensuring accuracy but limiting immediate insights for individuals.

The study marks a shift in how cognitive decline may be tracked in the future.

Instead of relying on infrequent clinical visits, researchers are moving toward continuous, real-world monitoring. Small, repeated measurements may provide a clearer picture than occasional large assessments.

This approach reflects a broader trend in medicine, where digital tools allow for more personalized and timely care.

For conditions like Alzheimer’s disease, where early detection is critical, this shift could make a meaningful difference.

This research could significantly change how cognitive decline is detected and managed. By enabling frequent, at-home testing, it offers a more sensitive and timely way to track memory changes.

In clinical trials, this approach could reduce the time needed to evaluate new treatments. Faster detection of changes means researchers can determine drug effectiveness sooner, potentially accelerating the development of therapies for Alzheimer’s disease and related conditions.

In clinical care, digital tools could support ongoing monitoring of patients. Doctors may use this data to adjust treatments earlier and more precisely. Patients could benefit from closer observation without needing frequent clinic visits.

The approach also improves accessibility. People in remote or underserved areas could participate in monitoring and research using devices they already own. This could expand participation in studies and improve understanding of cognitive health across populations.

Over time, digital memory testing may become part of routine healthcare. It could help identify early signs of decline, guide treatment decisions, and support efforts to maintain cognitive function as people age.

Research findings are available online in the journal npj Digital Medicine.

The original story "Smartphone memory tests detect Alzheimer’s decline months earlier" is published in The Brighter Side of News.

Like these kind of feel good stories? Get The Brighter Side of News' newsletter.